Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis

Molecular and Cellular Biology

Volumn 31, Issue 19, 2011, Pages 3997-4006

  Jung, Yong Sam ^a   Hakem, Anne ^b,c   Hakem, Razqallah ^b,c   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE ETA; LYSINE; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; CELL VIABILITY; DNA DAMAGE; DNA SYNTHESIS; GENE MUTATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; FIBROBLASTS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTATION; PROLIFERATING CELL NUCLEAR ANTIGEN; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; XERODERMA PIGMENTOSUM;

EID: 80053579178     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05808-11     Document Type: Article

References (30)

1. Bienko, M., et al. 2005. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis. Science 310:1821-1824.
2. Bienko, M., et al. 2010. Regulation of translesion synthesis DNA polymerase eta by monoubiquitination. Mol. Cell 37:396-407.
3. Boutet, S. C., M. H. Disatnik, L. S. Chan, K. Iori, and T. A. Rando. 2007. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 130:349-362.
4. Chen, B. B., and R. K. Mallampalli. 2009. Masking of a nuclear signal motif by monoubiquitination leads to mislocalization and degradation of the regulatory enzyme cytidylyltransferase. Mol. Cell. Biol. 29:3062-3075.
5. Chen, Y. W., et al. 2008. Human DNA polymerase eta activity and translocation is regulated by phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 105:16578-16583.
6. Cleaver, J. E., E. T. Lam, and I. Revet. 2009. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat. Rev. Genet. 10:756-768.
7. Duan, W., et al. 2004. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 96:1718-1721.
8. Friedberg, E. C., R. Wagner, and M. Radman. 2002. Specialized DNA polymerases, cellular survival, and the genesis of mutations. Science 296: 1627-1630.
9. Hicke, L., H. L. Schubert, and C. P. Hill. 2005. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 6:610-621.
10. Hoege, C., B. Pfander, G. L. Moldovan, G. Pyrowolakis, and S. Jentsch. 2002. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419:135-141.
11. Hoeijmakers, J. H. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411:366-374.
12. Isasa, M., et al. 2010. Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome. Mol. Cell 38:733-745.
13. Johnson, E. S., P. C. Ma, I. M. Ota, and A. Varshavsky. 1995. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270:17442-17456.
14. Johnson, R. E., C. M. Kondratick, S. Prakash, and L. Prakash. 1999. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 285:263-265.
15. Jung, Y. S., et al. 2008. Physical interactions and functional coupling between Daxx and sodium hydrogen exchanger 1 in ischemic cell death. J. Biol. Chem. 283:1018-1025.
16. Jung, Y. S., G. Liu, and X. Chen. 2010. Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. Mol. Cell. Biol. 30:1041-1048.
17. Kannouche, P. L., J. Wing, and A. R. Lehmann. 2004. Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol. Cell 14:491-500.
18. Kirkpatrick, D. S., et al. 2006. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat. Cell Biol. 8:700-710.
19. Laposa, R. R., L. Feeney, and J. E. Cleaver. 2003. Recapitulation of the cellular xeroderma pigmentosum-variant phenotypes using short interfering RNA for DNA polymerase H. Cancer Res. 63:3909-3912.
20. Leng, R. P., et al. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791.
21. Liu, G., and X. Chen. 2006. DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol. Cell. Biol. 26:1398-1413.
22. Logan, I. R., et al. 2006. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 26:6502-6510.
23. Logan, I. R., V. Sapountzi, L. Gaughan, D. E. Neal, and C. N. Robson. 2004. Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem. 279:11696-11704.
24. Masutani, C., et al. 1999. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 399:700-704.
25. Penengo, L., et al. 2006. Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin. Cell 124:1183-1195.
26. Plosky, B. S., et al. 2006. Controlling the subcellular localization of DNA polymerases iota and eta via interactions with ubiquitin. EMBO J. 25:2847-2855.
27. Prakash, S., R. E. Johnson, and L. Prakash. 2005. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu. Rev. Biochem. 74:317-353.
28. Sheng, Y., et al. 2008. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat. Struct. Mol. Biol. 15:1334-1342.
29. Shimada, M., et al. 2009. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci. 100:866-872.
30. Wang, L., et al. 2011. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol. Biol. Rep. 38:229-236.